Alexandra Worobec, M.D.

Articles by Alexandra Worobec, M.D.

A Risk-Based Approach to Immunogenicity Concerns of Therapeutic Protein Products, Part 3: Effects of Manufacturing Changes in Immunogenicity and the Utility of Animal Immunogenicity Studies

ByAmy S. Rosenberg, MD,Alexandra Worobec, M.D.

January 1st 2005

Manufacturing changes - such as changes in formulation or source material - can impact a product’s immunogenicity.

A Risk-Based Approach to Immunogenicity Concerns of Therapeutic Protein Products, Part 1: Considering Consequences of the Immune Response to a Protein

ByAmy S. Rosenberg, MD,Alexandra Worobec, M.D.

November 1st 2004

Neutralization of therapeutic protein products does not produce an obvious clinical deficiency syndrome for all therapeutic protein products with endogenous counterparts, because many endogenous proteins are biologically redundant.

Alexandra Worobec, M.D.

Articles by Alexandra Worobec, M.D.

A Risk-Based Approach to Immunogenicity Concerns of Therapeutic Protein Products, Part 3: Effects of Manufacturing Changes in Immunogenicity and the Utility of Animal Immunogenicity Studies

A Risk-Based Approach to Immunogenicity Concerns of Therapeutic Protein Products, Part 1: Considering Consequences of the Immune Response to a Protein

Latest Updated Articles

Trending on BioPharm International

BioPharm Brief: Gene Therapy Progress, FDA Approval, and $103M Funding

FDA Approves Roche’s Enspryng as First At-Home Subcutaneous Treatment for Thyroid Eye Disease

Opus Genetics’ OPGx-LCA5 Gene Therapy Shows Sustained Vision Gains Ahead of Phase 3

Estuary Biotherapeutics Launches With $103 Million for ADPKD Gene Therapy

Shift to In Vivo CAR T Will Reshape Facility Design, Says Arcadis’ Emily Heffernan